Last reviewed · How we verify
Moderate Neuromuscular Blockade
Moderate Neuromuscular Blockade, marketed by Menoufia University, holds a position in the neuromuscular blockade segment. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive positioning.
At a glance
| Generic name | Moderate Neuromuscular Blockade |
|---|---|
| Also known as | Rocuronium, Esmeron |
| Sponsor | Menoufia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
- The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer (PHASE2)
- Predicting The Right Advice at The Right Time in Patients With Hip and Knee OsteoArthritis: the e-cOAch Cross-over. (NA)
- Sustained Natural Apophyseal Glides With and Without Integrated Neuromuscular Inhibition Technique in Neck Pain (NA)
- The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders (NA)
- Low Pressure Pneumoperitoneum and Postoperative Ileus (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderate Neuromuscular Blockade CI brief — competitive landscape report
- Moderate Neuromuscular Blockade updates RSS · CI watch RSS
- Menoufia University portfolio CI